Abstract: A method to obtain a composition comprising an enriched population of functional mesenchymal stem cells for hypothermic transport and local administration of said enriched population of functional mesenchymal stem cells in therapy. Finally also described is the use of said enriched population of functional mesenchymal stem cells, and compositions comprising them, obtained by the described method, in autologous or allogeneic treatment of diseases susceptible to mesenchymal stem cell therapy, either by local or systemic treatments, and more particularly in the treatment of osteoarticular diseases such as degenerative disc disease, osteoarthritis, and bone repair; in lupus erythematosus, graft-versus-host disease, and other autoimmune diseases; in peripheral vascular insufficiency and other cardiovascular diseases.

Abstract: The present invention refers to compositions comprising recombinant biopolymers made of combinations of monomers of the type “Elastin-like recombinamers” (ELR), monomers comprising the “silk” sequence and/or monomers comprising the HLF sequence that belongs to a natural class of proteins named zippers. Said compositions are useful as bio-ink for 3D printing. Furthermore, the present invention also refers to methods for obtaining the composition of the invention, as well as the 3D biomaterial and to the different uses of the composition and the obtained biomaterial.

Abstract: An injectable elastin-like recombinamer (ELR) hydrogel for use in a method of treating a mammal that has suffered a myocardial infarction to modulate the response of cardiac muscle damaged by the infarct is described. The hydrogel is injected into the cardiac muscle damaged by the infarct at least two days after the myocardial infarction, and results in clinically significant repair of cardiac muscle evidenced by at least one or more of reduced scarring, positive remodelling of the damaged muscle, restoring cardiac muscle function to a clinically significant extent after infarction an improvement in angiogenesis, or a decreased pro-inflammatory response in the infarct zone, and typically within 10, 20 or 30 days of administration.

Abstract: The present invention relates to a biopolymer and a cell-harvesting scaffold comprising same, as well as the associated cell-harvesting method that allows said harvesting to be performed in a simple and effective manner by reducing the culture temperature. The present invention also relates to a method for synthesizing said biopolymer.

Abstract: Disclosed embodiments include a method and an apparatus for monitoring sleep apnea severity that comprise: (a) analyzing an oxygen saturation signal to extract a plurality of time-domain and frequency-domain metrics; (b) calculating an oxygen saturation-based Apnea Hyponea Index (AHI) by employing a predetermined functional mapping between said metrics and polysomnography (PSG)-based AHI; and (c) displaying an oxygen saturation-based AHI to enable a specialist to monitor sleep apnea severity without requiring PSG. According to a particular embodiment, the oxygen saturation signal is nocturnal oxygen saturation and the functional mapping is a multilinear regression model (MLR) or a multilayer perceptron network (MLP).

Abstract: The present invention relates to a sensor and device incorporating said sensor for obtaining data useful to determine the functional characteristics of the cornea in a non-invasive manner, particularly for establishing a correlation between the impedance at different frequencies and the permeability of the endothelium and epithelium and stromal hydration level.

Abstract: The present invention provides a therapeutic tool against intimal hyperplasia consisting of the use of Kv1.3 channel blocking substances, able to selectively stop cell migration and multiplication of VSMCs.

Abstract: The present invention relates to a biopolymer, bioactive and totally biocompatible, very fluid at ambient temperature, capable of gelling in a sudden manner at 37° C., forming a solid implant, structurally integral and continuous having high mechanical properties. The biopolymer comprises at least a bioactive domain capable of directing in a precise manner the formation of a solid or semisolid implant. Furthermore the invention relates to any of the nucleic acids encoding the amino acid sequence of the biopolymer, implants, pharmaceutically acceptable vehicles, uses thereof, and a method of synthesis thereof.

Abstract: Disclosed embodiments include a method and an apparatus for monitoring sleep apnea severity that comprise: (a) analyzing an oxygen saturation signal to extract a plurality of time-domain and frequency-domain metrics; (b) calculating an oxygen saturation-based Apnea Hyponea Index (AHI) by employing a predetermined functional mapping between said metrics and polysomnography (PSG)-based AHI; and (c) displaying an oxygen saturation-based AHI to enable a specialist to monitor sleep apnea severity without requiring PSG. According to a particular embodiment, the oxygen saturation signal is nocturnal oxygen saturation and the functional mapping is a multilinear regression model (MLR) or a multilayer perceptron network (MLP).

Abstract: The present invention discloses a method and related apparatus for determining a cardiac parameter from either the arterial blood pressure signal or the photoplethysmographic signal to quantify the degree of amplitude modulation due to respiration (pulse pressure variation) and predict fluid responsiveness. The method involves the application of Lempel-Ziv complexity to a filtered and segmented physiologic signal for direct determination of the fluid status of a patient. Real-time monitoring of fluid status involves the implementation of the disclosed method as part of a bedside monitoring apparatus.

Abstract: The present invention relates to a biopolymer, bioactive and totally biocompatible, very fluid at ambient temperature, capable of gelling in a sudden manner at 37° C., forming a solid implant, structurally integral and continuous having high mechanical properties. The biopolymer comprises at least a bioactive domain capable of directing in a precise manner the formation of a solid or semisolid implant. Furthermore the invention relates to any of the nucleic acids encoding the amino acid sequence of the biopolymer, implants, pharmaceutically acceptable vehicles, uses thereof, and a method of synthesis thereof.

Abstract: The present invention provides a therapeutic tool against intimal hyperplasia consisting of the use of Kv1.3 channel blocking substances, able to selectively stop cell migration and multiplication of VSMCs.

Abstract: The invention discloses ribosome inactivating proteins (RIPs) with two chains, which arc not toxic in the extra-cellular environment, of plant origin, and capable of interacting with ribonucleic acid and causing the inhibition of the biosynthesis of proteins in cellular systems, said proteins being comprised of two chains A and B, chain A having a N-glucosidase activity of the ribosomal ribonucleic acid, and chain B having a lectine activity, both chains being joined by disulphide bridges. Among the proteins, Nigrine b isolated from bark of Sambucus nigra L., basic Nigrine l isolated from the leaves of Sambucus nigra L., Ebuline 1 isolated from leaves of Sambucus ebulus L. and Racenosine b isolated from the bark of Sambucus racemosa L. are mentioned. The proteins find application as inactivators of the rebonucleic acid and as inhibitors of the protein synthesis.